Mineralys Therapeutics (MLYS) Enterprise Value (2023 - 2026)

Mineralys Therapeutics has reported Enterprise Value for 5 years, with the latest figure at -$644.9 million in Q1 2026.

• Quarterly Enterprise Value fell 88.02% year-over-year to -$644.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$644.9 million (down 88.02% YoY) and the FY2025 annual result came in at -$656.6 million, down 231.32% from the prior year.
• Enterprise Value climbed to -$644.9 million in Q1 2026 per MLYS's latest filing, from -$656.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$110.1 million in Q4 2022 and troughed at -$656.6 million in Q4 2025.
• A 5-year average of -$342.4 million and a median of -$289.4 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value rose 16.22% in 2024, then sank 231.32% in 2025.
• Over 5 years, Enterprise Value stood at -$110.1 million in 2022, then plunged by 114.85% to -$236.6 million in 2023, then grew by 16.22% to -$198.2 million in 2024, then tumbled by 231.32% to -$656.6 million in 2025, then rose by 1.78% to -$644.9 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$644.9 million, -$656.6 million, and -$593.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.